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Abstract
Annotations of gene structures and regulatory elements can inform genome-wide association studies
(GWAS). However, choosing the relevant annotations for interpreting an association study of a
given trait remains challenging. We describe a statistical model that uses association statistics
computed across the genome to identify classes of genomic element that are enriched or depleted
for loci that influence a trait. The model naturally incorporates multiple types of annotations.
We applied the model to GWAS of 18 human traits, including red blood cell traits, platelet traits,
glucose levels, lipid levels, height, BMI, and Crohn’s disease. For each trait, we evaluated the
relevance of 450 different genomic annotations, including protein-coding genes, enhancers, and
DNase-I hypersensitive sites in over a hundred tissues and cell lines. We show that the fraction
of phenotype-associated SNPs that influence protein sequence ranges from around 2% (for platelet
volume) up to around 20% (for LDL cholesterol); that repressed chromatin is significantly depleted
for SNPs associated with several traits; and that cell type-specific DNase-I hypersensitive sites
are enriched for SNPs associated with several traits (for example, the spleen in platelet volume).
Finally, by re-weighting each GWAS using information from functional genomics, we increase the
number of loci with high-confidence associations by around 5%.
1 Introduction
A fundamental goal of human genetics is to create a catalogue of the genetic polymorphisms that
cause phenotypic variation in our species and to characterize the precise molecular mechanisms by
which these polymorphisms exert their effects. An important tool in the modern human genetics
toolkit is the genome-wide association study, in which hundreds of thousands or millions of single
nucleotide polymorphisms (SNPs) are genotyped in large cohorts of individuals and each polymor-
phism tested for a statistical association with some trait of interest. In recent years, GWAS have
identified thousands of genomic regions that show reproducible statistical associations with a wide
array of phenotypes and diseases1.
In general, the loci identified in GWAS of multifactorial traits have small effect sizes and are
located outside of protein-coding exons2. This latter fact has generated considerable interest in
annotating other types of genomic elements apart from exons. For example, the ENCODE project
has generated detailed maps of histone modifications and transcription factor binding in six human
cell lines, partially motivated by the goal of interpreting GWAS signals that may act via a mech-
anism of gene regulation3. Methods for combining potentially rich sources of functional genomic
data with GWAS could in principle lead to important biological insights. The development of such
a method is the aim of this paper.
There are two lines of research that motivate our work on this problem. The first is what are
often called “enrichment” analyses. In this type of analysis, the most strongly associated SNPs
in a GWAS are examined to see if they fall disproportionately in specific types of genomic region.
These studies have found, for example, that SNPs identified in GWAS are enriched in protein-
coding exons, promoters, and untranslated regions (UTRs)2;4 and among those that influence gene
expression5;6. Further, in some cases, SNPs associated with a trait are enriched in gene regulatory
regions in specific cell types7–18 or near genes expressed in specific cell types19;20. However, the
methods in these studies are generally not able to consider more than a single annotation at a
time (with a few exceptions21;22). Further, they are not set up to answer a question that we find
important: consider two independent SNPs with equivalent P-values of 1×10−7 in a GWAS for some
trait (note that this P-value does not reach the standard threshold of 5× 10−8 for “significance”),
the first of which is a nonsynonymous SNP and the second of which falls far from any known gene.
What is the probability that the first SNP is truly associated with the trait, and how does this
compare to the probability for the second?
A potential answer to this question comes from the second line of research that motivates
this work. In association studies where the phenotype being studied is gene expression (“eQTL”
studies, for “expression quantitative trait locus”), statistical models have been developed to identify
shared characteristics of SNPs that influence gene expression23–25. In a hierarchical modeling
framework, the probability that a given SNP influences gene expression can then depend on these
characteristics. The key fact that makes these models useful in the context of eQTL mapping
is that there is a large number of unambiguous eQTLs in the genome on which a model can be
trained. In the GWAS context, the number of loci unambiguously associated with a given trait
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has historically been very small; learning the shared properties of two or three loci is not a job
well-suited to statistical modeling. However, large meta-analyses of GWAS now regularly identify
tens to hundreds of independent loci that influence a trait (e.g.26;27). The merits of hierarchical
modeling in this context28–30 are thus worth revisiting. Indeed, Carbonetto and Stephens31 have
reported success in identifying loci involved in autoimmune diseases using a hierarchical model that
incorporates information about groups of genes known to interact in a pathway.
In this paper we present a hierarchical model for jointly analyzing GWAS and genomic anno-
tations. We applied this model to GWAS of 18 diseases and traits; for each trait, we learned the
relevant types of genomic information from a set of 450 genome annotations.
2 Results
We assembled a set of 18 GWAS with publicly available summary statistics and a large number (at
least around 20) of loci associated with the trait of interest. These included studies of red blood cell
traits15, platelet traits32, Crohn’s disease33, BMI34, lipid levels27, height26, bone mineral density35
and fasting glucose levels36. We used ImpG37 to impute the summary statistics from each study
for all common SNPs identified in European populations by the 1000 Genomes Project38. Overall
we successfully imputed association statistics for around 80% of common SNPs (Supplementary
Figure 1). We then assembled a set of genome annotations, paying specific attention to annotations
available for many cell types since important regulatory elements may be active only in specific cell
types. The main sources of genome annotations were 402 maps of DNase-I hypersensitivity in a
wide range of primary cell types and cell lines11;39. We also included as annotations the output from
“genome segmentation” of the six main ENCODE cell lines40; for each section of the genome in
each cell line, Hoffman et al.40 report whether the histone modifications in the region are consistent
with enhancer activity, transcription start sites, promoter-flanking regions, CTCF binding sites, or
repressed chromatin. Finally, we included elements of gene structures (protein-coding exons and 3’
and 5’ UTRs). In total, we used data from 18 traits and 450 genomic annotations.
For each trait, we set out to identify which of the 450 annotations (if any) were enriched in
genetic variants influencing the trait. To do this, we developed a hierarchical model that learns
the shared properties of loci influencing a trait. The full details of the model are presented in
the Methods, but can be summarized briefly. Conceptually, we break the genome into large, non-
overlapping blocks (with an average size of 2.5 Mb). Let the prior probability that any block k
contains an association be Πk. If there is an association in block k, then let the prior probability
that any SNP i is the causal SNP be piik. We allow both Πk and piik to depend on annotations of
the region and SNP, respectively, and estimate these quantities based on the patterns of enrichment
across the whole genome. We tested this approach using simulations based on real data from a
GWAS of height (Supplementary Material).
The methodology is best illustrated with an example. We started with an analysis of a GWAS
of high-density lipoprotein (HDL) levels27. We first took each genomic annotation individually,
and estimated its level of enrichment (or depletion) for loci that influence HDL (in the model, we
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additionally included a regional effect of gene density and and a SNP-level effect of distance to the
nearest transcription start site, see the Methods for details). In Figure 1A, we show the top 40
annotations, ordered by how well each improves the fit of the model. Loci that influence HDL are
most strongly enriched in enhancers identified in the HepG2 cell line, and most strongly depleted
from genomic regions repressed in that same cell line. HepG2 cells are derived from a liver cancer;
the relevance of this cell line to a lipid phenotype makes intuitive sense. However, there are many
other additional (correlated) genome annotations that are enriched for loci that influence HDL
(Figure 1A). We thus built a model including multiple annotations; to mitigate over-fitting in this
situation we used a cross-validation approach (Methods). The best-fitting model is shown in Figure
1B. It include both enhancers and repressed chromatin identified in HepG2 cells, as well as coding
exons and chromatin repressed in K562 cells. Since many of the annotations are correlated, those
included in the combined model are the “best” representatives of sets of related annotations. We
thus used conditional analysis to define the set of annotations represented by each member of the
combined model (Methods; Figure 1A).
A convenient side effect of fitting an explicit statistical model relating properties of SNPs to
the probability of association is that we can use the functional information to re-weight the GWAS
(Methods). We used the combined model for HDL to re-weight the association statistics across the
genome (Figure 1C). There are several regions of the genome with strong evidence for association
with HDL (posterior probability of association [PPA] over 0.9) only when using the model incor-
porating functional information. In Figure 2, we show one such region, near the gene NR0B2. The
model identifies the SNP rs6659176 as the most likely candidate to be the causal polymorphism in
this region. This SNP has a P-value of 1.5× 10−6. However, this SNP falls falls in a coding exon
(in fact it is nonsynonymous), leading the model to conclude that this P-value is in fact strong
evidence for association. Indeed, larger studies of HDL have confirmed the evidence for association
in this region (P-value of 9.7× 10−16 at rs12748152, which has r2 = 0.85 with rs665917617). This
region, though not this particular SNP, was also identified in a scan for SNPs influencing multiple
lipid phenotypes41.
We applied this method to all 18 traits. We were first interested in estimating the fraction of
associations for each trait that can be explained by nonsynonymous polymorphisms versus polymor-
phisms that do not influence protein sequences. For each trait, we fit a model including promoters
(SNPs within 5kb of a transcription start site) as well as nonsynonymous polymorphisms. For all
traits, nonsynonymous polymorphsims are enriched among those that influence the trait, though
this enrichment is not statistically significant for all traits (Figure 3A). This contrasts with syn-
onymous polymorphisms, which are generally not enriched for polymorphisms that influence traits,
with a few notable exceptions (like height and Crohn’s disease, see Supplementary Figure 3). We
then used these enrichments to estimate the fraction of associations for each trait that are driven
by nonsynonymous polymorphisms (Supplementary Material). This fraction varies from around
2% to around 20%, with an average of 10% (Figure 3B). We conclude that the relative importance
of changes in protein sequence versus gene expression likely varies across traits.
We then used all 450 genome annotations to build models of enrichment for each trait. As for
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Figure 1. Application of the model to HDL cholesterol. A. Single-annotation models.
We fit the model to each annotation individually, including a SNP-level effect for SNPs 0-5kb from a
TSS, a SNP-level effect for SNPs 5-10kb from a TSS, a region-level effect for regions in the top third
of gene density, and a region-level effect for regions in the bottom third of gene density. Plotted are
the maximum likelihood estimates and 95% confidence intervals of the enrichment parameter for
each annotation. Annotations are ordered according to how much they improve the likelihood of
the model (at the top are those that improve the likelihood the most). In red are the annotations
included in the joint model, and in pink are the annotations that are statistically equivalent to those
included in the combined model. B. Joint model. Using the algorithm described in the Methods
we built a model combining multiple annotations. Shown are the maximum likelihood estimates
and 95% confidence intervals of the enrichment effects of each annotation. Note that though these
are the maximum likelihood estimates, model choice was performed using a penalized likelihood.
In parentheses next to each annotation (expect for those relating to distance to transcription start
sites), we show the total number of annotations that are statistically equivalent to the included
annotation in a conditional analysis. C. Re-weighted GWAS. We re-weighted the GWAS using
the model with all the annotations in B (under the penalized enrichment parameters from Sup-
plementary Table 9). Each point represents a region of the genome, and shown are the posterior
probabilities of association (PPA) of the region in the models with and without the annotations.
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Figure 2. Regional plot surrounding NR0B2. In the top panel we plot the P-values for
association with HDL levels at each SNP in this region. In the middle panel is the fitted empirical
prior probability that each SNP is the causal one in the region, conditional on there being a single
causal SNP in the region. This prior was estimated using the combined model with the annotations
in Figure 1B. In the lower panel are the positions of the annotations included in the model.* The
reported P-value is for rs12748152, which has r2 = 0.85 with rs6659176.
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Figure 3. Estimated role of protein-coding changes in each trait. A. Estimated en-
richment of non-synonymous SNPs. For each trait, we fit a model including an effect of
non-synonymous SNPs and an effect of SNPs within 5kb of a TSS. Shown are the estimated en-
richments parameters and 95% confidence intervals for the non-synonymous SNPs. B. Estimated
proportion of GWAS hits driven by non-synonymous SNPs. For each trait, using the
model fit in A., we estimated the proportion of GWAS signals driven by non-synonymous SNPs.
Shown is this estimate and its standard error (Supplementary Material).
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HDL, we first estimated enrichment levels individually for each annotation (Supplementary Figures
4-12). Clustering of phenotypes according to these enrichment levels recapitulated many known
relationships between traits (Supplementary Figure 13). We then generated a combined model for
each trait. The parameters of the combined models are shown in Figure 4 and Supplementary
Figure 14, and details of the exact annotations are in Supplementary Tables 2-20. In general,
the models generated with this method are sparse and biologically interpretable. A few general
patterns emerge from this analysis. Apart from the repeated occurrence of annotations related
to protein-coding genes, marks of repressed chromatin are often significantly depleted for SNPs
influencing traits. For example, SNPs influencing Crohn’s disease are depleted from repressed
chromatin identified in a lymphoblastoid cell line (Figure 4D; log2 enrichment of -1.83, 95% CI
[-3.06, -0.78]), SNPs influencing height are significantly depleted from repressed chromatin in HeLa
cells (Figure 4I; log2 enrichment of -1.5, 95% CI [-2.39, -0.71]), and SNPs influencing red blood
cell volume are significantly depleted from repressed chromatin in an erythroblast-derived cell line
(Figure 4F; log2 enrichment of -3.91, 95% CI [-6.25, -2.38]).
We additionally observed cell type-specific enrichments in enhancer elements and DNase hy-
persensitive sites for SNPs that influence traits. Most of the observed enrichments are readily
interpreted in light of the known biology of the trait. For example, SNPs that influence platelet
volume and platelet count are enriched in open chromatin identified in CD34+ cells, known to be
on the cell lineage that leads to platelets42 (Figure 4A,B; log2 enrichment of 1.81, 95% CI [0.59,
2.86] for platelet count; log2 enrichment of 3.02, 95% CI [1.69, 4.26] for platelet volume); and SNPs
that influence corpuscular hemoglobin concentration are enriched in open chromatin identified in
K562 cells, a cell line derived from a cancer of erythroblasts (Supplementary Figure 14E; log2 en-
richment of 2.67, 95% CI [0.61, 4.44]). For some traits, however, the connection between the trait
and the tissues identified is not immediately obvious. For example, SNPs associated with platelet
density are enriched in open chromatin in the spleen (Figure 4A; log2 enrichment of 1.93, 95% CI
[0.59, 3.14]), and SNPs associated with height are enrichment in open chromatin in muscle (Figure
4I; log2 enrichment of 2.27, 95% CI [1.51, 3.02]; note that though there are all a large number
of annotations equivalent to this annotation of open chromatin in fetal muscle, all of them are
muscle-related; see Supplementary Figure 5B).
For two traits–Crohn’s disease (Figure 4D) and red blood cell count (Supplementary Figure
14G)–we noticed that annotations initially identified as enriched for SNPs influencing the trait
ended up in the combined model as being depleted for SNPs influencing the trait. On further
examination (Supplementary Material), we found that these effects are due to statistical inter-
actions. For example, when treated alone, SNPs that influence Crohn’s disease are enriched in
DNase-I hypersensitive sites identified in fetal fibroblasts from the abdomen (log2 enrichment of
3.17, 95% CI [1.66, 4.36]). However, DNase-I hypersensitive sites identified in fetal fibroblasts from
the back show an even stronger enrichment (log2 enrichment of 4.21, 95% CI [2.99, 5.29]), and
sites in common between the two annotation are intermediate (log2 enrichment of 3.74, 95% CI
[2.29, 4.89]). This leads to an interaction where in the joint model the contribution of the DNase-I
hypersensitive sites identified in fetal abdominal fibroblasts is negative. Though this is a statistical
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Figure 4. Combined models for nine traits. For each trait, we built a combined model
of annotations using the algorithm presented in the Methods. Shown are the maximum likelihood
estimates and 95% confidence intervals for all annotations included in each model. Note that though
these are the maximum likelihood estimates, model choice was done using a penalized likelihood
(Methods). For the other nine traits, see Supplementary Figure 14. In parentheses next to each
annotation (expect for those relating to distance to transcription start sites), we show the total
number of annotations that are statistically equivalent to the included annotation in a conditional
analysis (Methods). *This annotation of DNase-I hypersensitive sites in fetal fibroblasts from the
abdomen has a positive effect when treated alone; see the text for discussion.
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explanation for this observation, the biological explanation is not immediately clear. It seems likely
that DNase-I hypersensitive sites are a heterogeneous set of different classes of elements, and that
different experiments are more sensitive, for either technical or biological reasons, to subsets of
these elements.
Finally, we explored the potential of this model to identify new loci (as in Figure 2). In order to
do this, one needs a threshold for “significance” in this model, ideally with similar properties as the
standard P-value threshold of 5× 10−8. To calibrate the method, we used the fact that we initially
applied our method to a study of four lipid traits that identified about 100 loci in a sample size of
around 90,000 individuals27. Since then, larger studies have raised the number of loci associated
with lipid traits to 15717. If we treat a locus with a P-value of 5 × 10−8 in the larger study as
a “true positive” and a locus that does not reach this threshold in the larger study as a “true
negative”, we can calibrate a threshold for posterior probability of association using the replication
data (Supplementary Material). We found that a threshold of a regional PPA of 0.9 performed
similarly to a stringent P-value threshold (Supplementary Figure 15). Combining the loci from both
the standard P-value approach and our approach resulted in an approximately 5% increase in the
number of identified loci while still maintaining a false positive rate close to zero (Supplementary
Figure 15, Supplementary Table 21). This is only a modest gain in power; that said, by applying
this method to all 18 traits we identified 49 loci that did not reach a standard statistical significance
threshold of 5 × 10−8 but have a PPA over 0.9 (Supplementary Table 22). Based on the above
results for lipids, the level of evidence that these loci are true positives is approximately the same
as those that have P = 5×10−8 in a standard GWAS. Indeed, the majority of these loci have since
been identified in larger cohorts than those used in this paper (Supplementary Table 22).
3 Discussion
In this paper, we have developed a statistical model for identifying genomic annotations that are
most relevant to the biology of a given phenotype. We have shown that this model is able to
scan through hundreds of genomic annotations to identify a sparse set of biologically-interpretable
annotations without prior knowledge of the biology of the phenotype.
Linking GWAS to biology
Perhaps the most striking observation is that chromatin annotated as repressed in a given cell
type is often depleted for SNPs that influence traits. Since approximately 60-70% of the genome
falls in this annotation in any given cell type (Supplementary Material), this information could
dramatically limit the number of SNPs considered when fine-mapping loci identified in GWAS.
Additionally, we identified several non-obvious connections between tissue and phenotypes. For
example, SNPs that influence platelet volume are enriched in DNAse-I hypersensitive sites in the
spleen (Figure 4A). Though the spleen functions in the removal of platelets from the bloodstream,
the connection between its function and platelet volume is unclear. An important next step will be
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to connect the identified non-coding variants in regulatory regions to changes in gene expression,
which is presumably the mechanism by which they exert an effect on phenotypes. Methods for
inferring the casual chain between variation in DNAse-I sensitivity, variation in gene expression,
and variation in phenotypes (e.g.41;43–46) will be essential.
Modeling assumptions
We have made several modeling assumptions that merit discussion. First, by splitting the genome
into blocks based on numbers of SNPs, we are making the implicit assumption that the probability
that a genomic region contains a SNP associated with a given phenotype depends on the SNP
density rather than the physical size–that is, a short genomic region with a large number of SNPs
is a priori as likely to have an association as a long genomic region with few SNPs. We have
also made a more restrictive assumption that there can be only a single causal SNP in a given
genomic region. This assumption is a natural starting point, but as GWAS sample sizes increase
even more it will begin to be untenable. Advances in methods for joint analysis of multiple SNPs
(e.g. Yang et al.47) may provide a way forward in this situation. Finally, we note that the model is
limited by the types of genomic annotations that are available, and the best annotations identified
in the model may be “proxies” for the truly-relevant annotations. For example, SNPs associated
with height are enriched in DNase-I hypersensitive sites identified in the fetal lung (Figure 4I);
taken literally, this would suggest that some SNPs influence height though lung development. An
alternative possibility, however, is that patterns of open chromatin in the lung (which is of course
a heterogeneous tissue) are useful proxies for patterns of open chromatin in a cell type that has not
been profiled; this hypothetical cell type could in principle be present in any tissue.
Prospects for fine-mapping GWAS loci using functional genomic data
We have primarily focused on using our model to identify annotations relevant to a trait of interest,
though we have also explored using this information to identify novel loci. A third natural appli-
cation, which we have not explored, is the possibility for fine-mapping GWAS loci using functional
genomic information48. Indeed, the posterior probability that each SNP in a given genomic re-
gion is the causal one is explicitly included in our model. However, in current applications around
20% of common SNPs are neither genotyped nor successfully imputed; this is a major limitation
to fine-mapping that cannot be overcome with statistical means. As GWAS move to even denser
genotyping or sequencing, we expect that re-visiting this issue will be fruitful.
Methods
In this section we detail the specifics of the hierarchical model; a description of the data used is
in the Supplementary Material. The model we propose is most closely related to that developed
by Veyrieras et al.23 in the context of eQTL mapping. Conceptually, we split the genome into
independent blocks, such that the blocks are larger than the extent of LD in the population. We
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then allow each block to contain either a single polymorphism that causally influences the trait
or none. We model the prior probability that any given block contains an association and the
conditional prior probability that any given SNP in the block is the causal one. The key is that
we allow these probabilities to vary according to functional annotations–for example, gene-rich
regions might be more likely to contain associations, and if there is an association, the causal
polymorphism may be more likely to fall in a transcription factor binding site. We then estimate
these priors using an empirical Bayes approach. Software implementing this model is available at
https://github.com/joepickrell/fgwas.
Computing the Bayes factor
The basic building block of the model is a linear regression model. Consider a single SNP geno-
typed in N phenotyped individuals. Assume each individual has an associated measurement of a
quantitative trait (we describe a slight modification for case-control studies later), and let ~y be the
vector of phenotypes. Let ~g be the vector of genotypes (coded 0, 1, or 2 according to counts of an
arbitrarily-defined allele). We use a standard additive linear model:
E[yi] = α+ βgi. (1)
We would like to compare two models: one where β = 0 and one where β 6= 0. A natural way to
compare these two models is the Bayes factor:
BF =
∫
P (~y|~g,H1)∫
P (~y|~g,H0) , (2)
where H1 and H0 represent the parameters of the the alternative and null models, respectively, and
which are integrated out.
To compute Equation 2, we use the approximate Bayes factor from Wakefield49. This Bayes
factor has the practically important property that is can be calculated from a summary of the linear
regression, without access to the underlying genotype vector ~g. For completeness, we re-iterate here
the underlying model. If βˆ is the maximum likelihood estimator of β and
√
V is the standard error
of βˆ, Wakefield49 suggests a model in which:
βˆ ∼ N(β, V ). (3)
Wakefield49 places a normal prior on β, such that β ∼ N(0,W ). Under this model Equation 2
becomes:
BF =
√
1− r
exp[−Z22 r]
, (4)
where r = WV+W and Z =
βˆ√
V
(a standard Z-score). Thus, from a Z-score, an estimate of V , and
the prior variance W , we can obtain a Bayes factor measuring the statistical support for a model
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in which a SNP is associated with a trait as compared to a model in which a SNP is not associated
with a trait. Note, however, that because of linkage disequilibrium in the genome, any true causal
association will lead to multiple true statistical associations. In all applications, we set W = 0.1
as the prior, such that the majority of the weight of the prior is on small effect sizes (results are
robust to some variation in this prior; see Supplementary Material and Supplementary Figure 16).
Hierarchical model
Now consider a set of M SNPs, each of which has been genotyped in N individuals in a GWAS.
Our goal is to build a model to identify the shared characteristics of SNPs that causally influence a
trait. Because of LD, there will be many associations in the genome that are not causal; however,
these will all be restricted to a block around the truly causal site. We thus split the genome into
contiguous blocks of size K SNPs (in all of our applications, we set K = 5, 000, though doubling this
block size had little effect on the results; see Supplementary Material and Supplementary Figure
16), such that there are M/K blocks. We choose the block size to be much larger than the extent
of linkage disequilibrium in the population. Let Πk be the prior probability that block k contains a
causal SNP associated with the trait. The probability of the data (the set of observed phenotypes)
is then:
P (~y) =
M/K∏
k=1
(1−Πk)P 0k + ΠkP 1k , (5)
where P 0k is the probability of the data in block k under the model where there are no SNPs
associated with the trait in the block, and P 1k is the probability of the data in block k under the
model where there is one SNP associated with the trait in the block. Further,
P 1k =
∑
i∈Sk
piikP
1
ik, (6)
where Sk is the set of SNPs in block k, piik is the prior probability that SNP i is the causal SNP
in the region conditional on there being an association in block k, and P 1ik is the probability of the
data under the model where this SNP is associated with the trait. Note that this is not a multiple
regression model where we jointly model the effects of multiple SNPs on a trait (as in, for example,
Carbonetto and Stephens31).
We can now allow the prior probabilities–both Πk (the prior on the block of SNPs containing an
association) and piik (the prior probability that SNP i is the causal SNP assuming there is a single
association in block k)–to depend on external information. We would also like to avoid subjective
variation in Πk and pii, but instead learn from the data itself which genomic annotations are most
important. Specifically, we model the regional prior probability as:
ln
(
Πk
1−Πk
)
= κ+
L1∑
l=1
γlIkl, (7)
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where L1 is the number of region-level annotations in the model, γl is the effect associated with
annotation l and Ikl takes the value 1 if region k is annotated with annotation l and 0 otherwise.
For example, in practice we will estimate a γ parameter for regions of high or low gene density. We
then model the SNP prior probability as:
piik =
exi∑
j∈Sk
exj
, (8)
where
xi =
L2∑
l=1
λlIil, (9)
where L2 is the number of SNP-level annotations in the model, λl is the effect of SNP annotation
l and Iil takes the value 1 if SNP i falls in annotation l and 0 otherwise. For example, in practice
we will estimate a λ parameter for nonsynonymous SNPs.
Fitting the model
Combining terms above, we see that the likelihood of the data can be written down as:
L(~y|θ) =
M/K∏
k=0
(1−Πk)P 0k + Πk
K∑
i=0
piijP
1
ik (10)
=
M/K∏
k=0
P 0k [(1−Πk) + Πk
K∑
i=0
piikBFi], (11)
where θ is contains all the parameters of the model, most notably the set of annotation parameters.
We maximize this function using the Nelder-Mead algorithm implemented in the GNU Scientific
Library.
Shrinkage estimators of the annotation parameters
While maximizing Equation 10 gives the maximum likelihood estimates of all parameters, one
concern is that there may be some level of overfitting. When comparing models, we instead shrink
these parameters towards zero. Specifically, we define a penalized log-likelihood function:
l∗(~y|θ) = ln
(
(L(~y|θ)
)
− p
( L1∑
l=1
γ2l +
L2∑
l=1
λ2l
)
. (12)
The penalty p on the sum of the squared annotation parameters is the one used in ridge regres-
sion50. In ridge regression, parameter estimates under this penalty are equivalent to estimating the
posterior mean of the parameter if the prior distribution of the parameter is Gaussian50; changing
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the tuning parameter p is equivalent to changing the prior. We suspect that the interpretation in
this model is similar. Since this penalized likelihood can not be used for formal statistical tests, we
tune the p parameter by cross-validation. An alternative approach here would be to explicitly put
a prior on the enrichment parameters, but in the absence of a conjugate prior this would likely add
substantially to the computational burden for little practical benefit.
Cross-validation
To compare models and tune the penalty p in the penalized likelihood above, we used a 10-fold
cross-validation approach. We split the chromosomal segments into 10 folds. Let θp−f be the
parameters of the model estimated while holding out the data from fold f and under penalty p,
and l∗f (θ
p
−f ) be the penalized log-likelihood of the data in fold f under the model optimized without
using fold f . Then:
l
′
(θp) =
1
10
10∑
i=1
l∗i (θ
p
−i). (13)
Note that the size of the folds used in this cross-validation means that each fold excludes more
than an entire chromosome. This means that no individual chromosome can have undue influence
on the parameters included in the model.
Model choice
Consider a single phenotype and a set of L functional annotations of SNPs (in our case L is in
the hundreds). Including all L SNP annotations in the model is neither biologically interesting nor
computationally feasible. We thus set out to choose a relatively sparse model that fits the data. We
start with forward selection: for each of the L annotations, we fit a model including a region-level
parameter for regions in the top third of the distribution of gene density, a region-level parameter
for regions in the bottom third of the distribution of gene density, a SNP-level parameter for SNPs
from 0-5 kb from a TSS, a SNP-level parameter for SNPs from 5-10kb from a TSS, and a SNP-level
parameter for the annotation in question. We then identify the set of annotations that significantly
improve the model fit (as judged by the likelihood from Equation 10). We then:
1. Add the annotation that most significantly improves the likelihood to the model.
2. For each annotation identified as having a significant marginal effect, test a model including
the annotation and those that have already been added.
3. If any annotation remains significant, go back to step 1.
At this point, there are generally a small number of annotations in the model, but the model
may be over-fit. We then switch to using the 10-fold cross-validation likelihood in Equation 13.
We first tune the penalty parameter p by finding the value of p that maximizes the cross-validation
likelihood. We then:
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1. Drop each annotation from the model in turn, and evaluate the cross-validation likelihood.
When dropping annotations, we additionally try dropping the region-level annotations on
gene density and the SNP-level annotations on distance to the nearest TSS.
2. If a simpler model has a higher cross-validation likelihood than the full model, drop the
annotation from the model and return to step 1.
3. Report the model that has the highest cross-validation likelihood.
Approximating Vi
In order to compute the Bayes factor in Equation 4, we need an estimate of Vi, the standard
error of the estimated effect size of SNP i. In principle, this is trivial output from standard
regression software; however, it is rarely reported. Instead, let fi be the minor allele frequency
of SNP i computed from an external sample of the same ancestry as the population in which the
association study was done (we use data from the 1000 Genomes Project38). Let Ni be the number
of individuals in the association study at SNP i (this can vary across SNPs due to missing data).
Then:
Vi ≈ 1
Nifi(1− fi) . (14)
Note that this variance is independent of the actual scale of the measurements; this is appropriate
because the Z-scores are independent of the scale of the measurements as well.
Case-control studies
For all of the above, we have considered studies of quantitative traits. For a case-control study, we
assume that we have summary statistics from logistic regression instead of linear regression. All
aspects of the model are identical, with the exception of the approximation of Vi. Define Ncase and
Ncontrol as the numbers of cases and controls, respectively. Now,
49:
Vi ≈ Ncase +Ncontrol
NcaseNcontrol[2fi(1− fi) + 4f2i − (2fi(1− fi) + 4f2i )2]
. (15)
The variance here is on a log-odds scale.
Posterior probabilities of association
Once the model has been fit, we have empirical estimates of the prior probability that region k
contains an association, Πˆk and the prior probability that SNP i is the causal one, pˆiik (conditional
on there being an association). We define a Bayes factor summarizing the evidence for association
in the region (see, for example Maller et al.48):
BFRk =
∑
i∈Sk
pˆiikBFi, (16)
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where Sk is the set of SNPs in region k and BFi is the Bayes factor for SNP i (Equation 4). The
posterior probability that region k contains an association is then:
PPARk =
ΠˆkBF
R
k /(1− Πˆk)
1 + ΠˆkBF
R
k /(1− Πˆk)
(17)
We can also define the posterior probability that any given SNP i in region k is the causal one
under our model:
PPAik =
pˆiikBFi∑
j∈Sk
pˆijkBFj
. (18)
This is similar to the calculation in Maller et al.48, except that we allow the prior probability piik
to vary across SNPs.
Finally, we can define the posterior probability that any given SNP is causal. This is the
posterior probability that the region contains a causal SNP times the posterior probability that the
SNP is causal conditional on there being an association in the region. If SNP i falls in region k:
PPAi = PPA
R
k PPAik. (19)
Conditional analysis
Because many of the annotations we consider are correlated, those ultimately included in the
combined model for each trait (Figure 4) may be representatives of a large group of correlated
annotations. For biological interpretation of the model, it is thus important to know which of the
other annotations are interchangeable with those included in the model.
To test this, we took an approach of conditional analysis. Consider two SNP-level annotations,
with annotation parameters λ1 and λ2, respectively. In a joint model, we would jointly estimate
both λ1 and λ2. However, we are interested in whether the second annotation adds information
above and beyond that provided by the first annotation. We thus first estimate λ1, then fix this
parameter to its maximum likelihood value λˆ1. We then estimate λ2|λˆ1 – that is, we obtain the
maximum likelihood estimate and 95% confidence interval of λ2 conditional on a fixed value of λ1.
If this confidence interval does not overlap zero, this is evidence that the second annotation adds
information to the model above that provided by the first.
In practice, we first fit the combined model as described in the section “Model choice” above.
We then returned to the set of annotations that had significant marginal associations. For each
annotation in the combined model, we took each of the other annotations in turn and tested whether
the included annotation was significantly more informative than the non-included annotation. In
Figure 4 and Supplementary Figure 12, we display the total number of annotations represented by
each one that is included in the combined model.
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1 GWAS data
1.1 GIANT data
We downloaded summary statistics from large GWAS of height [Lango-Allen et al., 2010] and BMI
[Speliotes et al., 2010] from http://www.broadinstitute.org/collaboration/giant/index.php/
GIANT_consortium. The height summary statistics consisted of 2,469,635 SNPs either directly
genotyped or imputed in an average of 129,945 individuals. We removed all SNPs with a sample
size of less than 120,000 individuals. The BMI summary statistics consisted of 2,471,516 summary
statistics either directly genotyped or imputed in an average of 120,569 individuals. We removed
all SNPs with a sample size of less than 110,000 individuals. We then imputed summary statistics
at SNPs identified in the 1000 Genomes Project as described in Section 3.
1.2 GEFOS data
We downloaded summary statistics from large GWAS of bone mineral density [Estrada et al., 2012]
from http://www.gefos.org/?q=content/data-release. There are two traits in these data:
bone density measured in the femoral neck and bone density measured in the lumbar spine. The
femoral neck bone density GWAS consisted of 2,478,337 SNPs, and the lumbar spine bone density
consisted of 2,468,080 SNPs. Because the sample size at each SNP was not reported, we used the
overall study sample sizes of 32,961 and 31,800 as approximations of the sample size at each SNP,
and imputed summary statistics as described in Section 3.
1.3 IIBDGC data
We downloaded summary statistics from a large GWAS of Crohn’s disease [Jostins et al., 2012]
from http://www.ibdgenetics.org/downloads.html. The downloaded data consisted of 953,242
SNPs. Because the sample size at each SNP was not reported, we used the overall study sample
sizes of 6,299 cases and 15,148 controls as approximations of the sample size at each SNP, and
imputed summary statistics as described in Section 3. Note that summary statistics from a GWAS
of ulcerative colitis were also available from this site; however, these data contain a number of false
positive associations that were filtered by Jostins et al. [2012] using criteria that were not available
to us. We thus only used the Crohn’s disease association study.
1.4 MAGIC data
We downloaded summary statistics from a large GWAS of fasting glucose levels [Manning et al.,
2012] from http://www.magicinvestigators.org/downloads/. The downloaded data consisted
of 2,628,880 SNPs. Because the sample size at each SNP was not reported, we used the overall
study sample size of 58,074 as an approximation of the sample size at each SNP, and imputed
summary statistics as described in Section 3.
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1.5 Global lipid genetics consortium data
We downloaded summary statistics from a large GWAS of lipid traits [Teslovich et al., 2010] from
http://www.sph.umich.edu/csg/abecasis/public/lipids2010/. These data consist of sum-
mary statistics for association studies of four traits: LDL cholesterol, HDL cholesterol, trigylcerides,
and total cholesterol. The HDL data consisted of 2,692,429 SNPs genotyped or imputed in an av-
erage of 88,754 individuals, the LDL data consisted of 2,692,564 SNPs genotyped or imputed in an
average of 84,685 individuals, the total cholesterol data consisted of 2,692,413 SNPs genotyped or
imputed in an average of 89,005 individuals, and the triglycerides data consisted of 2,692,560 SNPs
genotypes or imputed in an average of 85,691 individuals. For all traits, we removed SNPs with a
sample size less than 80,000 individuals, and imputed summary statistics as described in Section 3.
To calibrate significance thresholds, we additionally used summary statistics from Global Lipids
Genetics Consortium et al. [2013]. These were downloaded from http://www.sph.umich.edu/csg/
abecasis/public/lipids2013/.
1.6 Red blood cell trait data
We obtained summary statistics from a large GWAS of red blood cell traits [van der Harst et al.,
2012] from the European Genome-Phenome Archive (accession number EGAS00000000132). We
downloaded summary statistics from association studies of six traits: hemoglobin levels, mean
cell hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean cell volume
(MCV), packed cell volume (PCV), and red blood cell count (RBC). The hemoglobin level data
consisted of 2,593,078 SNPs genotyped or imputed in 50,709 individuals, the MCH data consisted
of 2,586,785 SNPs genotyped or imputed in an average of 43,127 individuals, the MCHC data
consisted of 2,588,875 SNPs genotyped or imputed in an average of 46,469 individuals, the MCV
data consisted of 2,591,132 SNPs genotyped or imputed in an average of 47,965 individuals, the PCV
data consisted of 2,591,079 SNPs genotyped or imputed in an average of 44,485 individuals, and the
RBC data consisted of 2,589,454 SNPs genotyped or imputed in an average of 44,851 individuals.
We removed all SNPs with a sample size of less than 50,000 individuals (for hemoglobin levels) or
40,000 individuals (for the other traits), and imputed summary statistics as described in Section 3.
1.7 Platelet traits
Summary statistics from a large GWAS of platelet traits [Gieger et al., 2011] were generously
provided to us by Nicole Soranzo. The data consist of summary statistics from association studies
of two traits: platelet counts and mean platelet volume. The platelet count data consisted of
2,705,636 SNPs genotyped or imputed in an average of 44,217 individuals, and the platelet volume
data consisted of 2,690,858 SNPs genotyped or imputed in an average of 16,745 individuals. We
removed all SNPs with sample sizes less than 40,000 (for platelet counts) or 15,000 (for platelet
volume), and imputed summary statistics as described in Section 3.
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2 Functional genomic data
2.1 DNase-I hypersensitivity data
We downloaded DNase-I hypersensitivity data from two sources. The first was a set of regions
defined as DNase-I hypersensitive by Maurano et al. [2012] in 349 samples. We downloaded .bed
files for 349 samples from http://www.uwencode.org/proj/Science_Maurano_Humbert_et_al/
on February 13, 2013. These samples include 116 samples from cell lines or sorted blood cells, and
333 samples from primary fetal tissues. These latter samples were sampled from several tissues at
various time points; we treated each track as independent rather than pooling data from tissues,
since different experiments may have slightly different properties. The tissues in this latter group
are fetal heart, fetal brain, fetal lung, fetal kidney, fetal intestine (large and small), fetal muscle,
fetal placenta, and fetal skin.
The second was a set of regions defined as DNase-I hypersensitive by the Crawford lab in the con-
text of the ENCODE project [Thurman et al., 2012]. We downloaded .bed files for 53 samples from
http://ftp.ebi.ac.uk/pub/databases/ensembl/encode/integration_data_jan2011/byDataType/
openchrom/jan2011/fdrPeaks/ on March 29, 2013. We restricted ourselves to the files labeled as
being generated at Duke University. Each experiment defined a set of regions of open chromatin
in a particular cell type or cell line.
The “Duke” DNase-I hypersensitive sites are all of exactly 150 bases in length, and each anno-
tation covers approximately 1% of the genome (range: 0.4 - 1.9 % of the genome). The “Maurano”
DNase-I hypersensitive sites are on average 514 bases long, and each covers on average 2.7% of the
genome (range: 0.9-5.1 % of the genome).
2.2 Chromatin state data
We downloaded the “genome segmentations” of the six ENCODE cell lines [Hoffman et al., 2013]
from http://ftp.ebi.ac.uk/pub/databases/ensembl/encode/integration_data_jan2011/byDataType/
segmentations/jan2011/hub/ on December 18, 2012. We used the “combined” segmentation
from two algorithms. This segmentation splits the genome into non-overlapping regions described
as CTCF binding sites, enhancers, promoter-flanking regions, repressed chromatin, transcribed re-
gions, transcription start sites, and weak enhancers. This segmentation was done independently in
each of six cell lines, for a total of 42 annotations.
Overall the “repressed chromatin” mark covers the largest fraction of the genome, on average
66% (ranging from 60% for HUVEC cells to 70% for H1 ES cells). The “transcribed” mark covers on
average 13% of the genome, the “CTCF” mark 1% of the genome, the “enhancer” mark 0.9% of the
genome, the “TSS” mark 0.7% of the genome, the “weak enhancer” mark 0.4% of the genome, and
the “promoter-flanking” mark 0.2% of the genome. The remainder of the genome is not mappable
by short reads and it thus excluded from these annotations.
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2.3 Gene models
We downloaded the Ensembl gene annotations from the UCSC genome browser on May 21. Annota-
tions of nonsynonymous and synonymous status for all SNPs in phase 1 of the 1000 Genomes Project
were obtained from ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/phase1/analysis_results/
functional_annotation/annotated_vcfs/. Coding exons cover about 3% of the genome, while
3’ UTRs and 5’ UTRs cover 2% and 0.6% of the genome, respectively.
3 Imputation of summary statistics
We used ImpG v1.0 [Pasaniuc et al., 2013] under the default settings to impute summary statistics
from all GWAS. As a reference panel, we used all haplotypes from European individuals in phase 1
of the 1000 Genomes Project, and only used SNPs with a minor allele frequency greater than 2%.
The reference haplotype files were derived from the 1000 Genomes integrated phase 1 v3.20101123
calls, downloaded from ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/phase1/analysis_
results/integrated_call_sets/. We used all 379 individuals labeled as “European”. After
imputation, we removed all imputed SNPs with a predicted accuracy (in terms of correlation with
the true summary statistics) less than 0.8. Overall, for each GWAS, we successfully imputed about
75-80% of SNPs with a minor allele frequency over 10% (Figure 1).
To verify that imputation did not induce inflation of the test statistics, we computed the genomic
control inflation factor λGC [Bacanu et al., 2002] before and after imputation (Supplementary Table
1). In all studies, inflation decreased after imputation, sometimes leading to a marked deflation in
the test statistics. This is consistent with previous observations using this software [Pasaniuc et al.,
2013]. The reason for this deflation is the shrinkage prior used in the imputation, which leads to
conservative estimates of significance (imposed to strictly avoid false positive associations).
4 Details of application of the hierarchical model
4.1 Simulations
To test the performance of the model, we performed simulations using a GWAS of height [Lango-
Allen et al., 2010]. Using the imputed summary statistics, we split the genome into blocks of 5,000
SNPs, then extracted the blocks with a genome-wide significant SNP reported in Lango-Allen et al.
[2010]. In each block, we had a reported Z-score for each SNP. To simulate annotations, we called
the SNP with the smallest P-value in the region the “causal” SNP. We then simulated annotations
by placing all non-“casual” SNPs in an annotation with rate r1, and all “casual” SNPs in the
annotation with rate r2. We also varied the numbers of blocks included in the model. In each
simulation, we randomly assigned SNPs to annotations according to determined rates, then ran
our model under the assumption that Πk = 1, that is, all blocks contain a causal SNP. We then
calculated power as the fraction of simulations in which the confidence intervals of the annotation
effect did not overlap zero.
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We chose parameter settings of r1 and r2 such that the enrichment factors were similar to those
in observed data (log-enrichment of 0.98 and 1.80). We chose r1 to be either 0.2 and 0.1. For each
set of parameters, we simulated 100 annotations and ran the model separately on each. Shown in
Figure 2 is the power of the model. As expected, power increased as r1 or the effect size increased,
and as the number of loci increased.
4.2 Robustness to choice of prior and window size
There are two parameters in the model that are set by the user–the prior variance W on the effect
size and the window size defining “independent” blocks of the genome. We empirically tested
the robustness of the model to variation in these parameters using the Crohn’s disease dataset.
We ran the model on each annotation using W = 0.1 and W = 0.5, additionally including–as in
our main analyses–region-level parameters for regions in the top third and bottom third of gene
density and SNP-level parameters for SNPs located from 0-5kb from a transcription start site and
SNPs 5-10kb from a transcription start site. Plotted in Figure 16A are these annotation parameter
estimates for all annotations where the 95% confidence intervals did not overlap 0 in at least one
run. The estimates from the two runs with different priors are highly correlated. We additionally
tested window sizes of 5,000 SNPs and 10,000 SNPs (both with W = 0.1). The annotation effect
estimates from these two window sizes are plotted in Figure 16B, and again are highly correlated.
4.3 Quantifying the relative roles of coding versus non-coding changes in each
phenotype
To generate Figure 3 in the main text, we fit a model to each GWAS where we included region-level
annotations for regions in the top third and bottom third of the distribution of gene density, and
SNP-level annotations for non-synonymous SNPs and SNPs within 5kb of a transcription start
site. Shown in Figure 3A in the main text are the estimates of the enrichment parameter for non-
synonymous SNPs. At each SNP, the result of this model is the posterior probability that the SNP
is casual (see Equation 19 in the main text). If we let this posterior probability at SNP i be PPAi,
then the fraction of causal SNPs that are non-synonymous, fNS is:
fNS =
∑
i PPAiI
NS
i∑
i PPAi
, (1)
where INSi is an indicator variable that takes value one if SNP i is non-synonymous and zero
otherwise. To get error bars on this fraction, we performed a block jackknife. We split the genome
into 20 blocks with equal numbers of SNPs. If f jNS is the estimate of the fraction of casual SNPs
that are non-synonymous excluding block j, then:
SE =
√√√√19
20
20∑
j=1
(f jNS − f¯NS)2, (2)
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where f¯NS =
1
20
20∑
i=1
f iNS . In Supplementary Figure 3, we show the corresponding results for syn-
onymous SNPs.
4.4 Interaction effects in annotation models
As noted in the main text, there were two cases in which the sign of the annotation effect flipped
between the single annotation models and the combined models. These were Crohn’s disease
(Supplementary Table 6) and red blood cell count (Supplementary Table 18). In the main text
we discuss the Crohn’s disease example. For the red blood cell count example, note that SNPs
influencing this trait are enriched in the annotation of DNAse-I hypersensitive sites in the fetal
renal pelvis when this annotation is considered alone (log2 enrichment of 2.48, 95% CI [0.04, 4.17]).
This annotation is correlated with the fetal stomach annotation, which has a log2 enrichment of
4.83 (95% CI [3.30, 6.45]) when treated alone. The SNPs in both of these annotations have a
log2 enrichment of 2.41 (95% CI [-1.83, 4.23]), which leads to the interaction effect. Essentially
the signal in the fetal stomach is driven by those SNPs that fall in DNase-I hypersensitive sites in
the fetal stomach but not the fetal renal pelvis. This suggests that there are a subset of DNase-I
hypersensitive sites that are of particular interest for this phenotype. The interpretation of the
Crohn’s disease example is similar.
4.5 Calibrating a “significance” threshold
For each genomic region, our method estimates the posterior probability that the region contains
a SNP associated with a trait. If the model were a perfect description of reality, this probability
could be interpreted literally. Since the model is not perfect, however, we sought a more empirical
calibration. We used the fact that we initially ran the method on the GWAS data reported by
Teslovich et al. [2010] on four lipid traits. Since then, a GWAS with more individuals (though
at a considerably smaller number of SNPs) has been reported for these four traits [Global Lipids
Genetics Consortium et al., 2013]. This latter study contains many of the individuals from the
former (which had approximately 90,000 individuals), as well as about 80,000 more individuals.
However, the additional individuals were genotyped in the Metabochip [Voight et al., 2012], which
has less than 200,000 markers, rather than the more dense standard GWAS arrays. This means
that some regions of the genome do not benefit from the larger sample size.
For each region of the genome for each of the four traits, we built a table containing the
minimum P-value from Teslovich et al. [2010], the posterior probability of association in the region
(computed using the data from Teslovich et al. [2010]), the minimum P-value from Global Lipids
Genetics Consortium et al. [2013], and the sample size used to get this minimum P-value (from
Global Lipids Genetics Consortium et al. [2013]). We discarded regions where sample size at the
SNP with the minimum P-value in the replication data set was smaller than 120,000 (since in these
regions there is essentially no new data). We then coded each region as a “true positive” if the
minimum P-value from Global Lipids Genetics Consortium et al. [2013] was less than 5 × 10−8
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and a “true negative” otherwise. In Figure 15, we plot the number of “true positives” and “false
negatives” that exceed various P-value and PPA thresholds. Note that since the data in Global
Lipids Genetics Consortium et al. [2013] is not independent of that in Teslovich et al. [2010], this
comparison is not appropriate for evaluating the relative performance of P-values versus the PPA.
Our goal was simply to find a PPA threshold with similar performance in terms of reducing the
number of false positives as the standard P-value threshold of 5× 10−8.
By visual inspection we set a PPA threshold at 0.9 (Figure 15). At this threshold, we identify
45 “true positives” and zero “false positives” for HDL, 43 and 1 for LDL, 47 and zero for total
cholesterol, and 27 and zero for triglycerides. These are similar to the numbers for a P-value
threshold of 5 × 10−8 (Supplementary Table 21). Combining the loci identified by both methods
leads to 48 loci for HDL (versus 43 using a P-value threshold), 44 for LDL (versus 40), 51 for TC
(versus 51) and 30 for TG (versus 29). This is on average an increase of 6% in the number of
loci identified. Note that this number is likely a lower bound, since the P-values in the replication
study are naturally highly correlated to those in the initial study since they use many of the same
individuals. A proper comparison would use a completely separate, large set of individuals to
determine “true positives” and “true negatives”, but such samples are not yet available.
4.6 Identification of novel loci
For each fitted model (using the parameters from Supplementary Tables 3-20 estimated using the
penalized likelihood), we calculated the posterior probability of association in each genomic region.
We then identified all regions with a PPA greater than 0.9 but that had a minimum P-value less
than 5×10−8. For each remaining region, we identified the “lead” SNP as the SNP with the largest
posterior probability of being the causal SNP in the region. If this SNP was within 500kb of a
SNP with P < 5× 10−8 (this can happen because we use non-overlapping windows and sometimes
the best SNP is at the edge of the region), we removed it. We also manually removed two regions
(surrounding rs8076131 in Crohn’s disease and surrounding rs11535944 in HDL), where the “new”
association was in LD with a previously reported SNP over 500kb away. In Supplementary Table
22, we show the remaining SNPs; these regions are high-confidence associations that did not reach
traditional genome-wide significance.
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Figure 1. Proportion of SNPs in the 1000 Genomes Project either genotyped or suc-
cessfully imputed. For each trait, we split all SNPs in phase 1 of the 1000 Genomes Project into
bins based on their minor allele frequency in the European population. Bin sizes were of 5% fre-
quency. Shown are the proportions of SNPs in each bin that were either genotyped or successfully
imputed for each trait (the points are at the lower ends of the bins, such that the point at 45%
frequency contains all SNPs from 45%-50% minor allele frequency). Labeled are the traits with
the lowest and highest coverage. HB = hemogobin levels, FNBMD = femoral neck bone mineral
density.
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Figure 2. Power to detect a significant annotation. We simulated GWAS data under different
levels of enrichment of causal SNPs in an annotation (see Supplementary Text), then evaluated the
power of the method to detect the enrichment with different numbers of loci. In red and pink are
log2-enrichments of 2.6, and in black and grey are log2-enrichments of 1.4.
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Figure 3. Estimated role of synonymous polymorphisms in each trait. A. Estimated
enrichment of synonymous SNPs. For each trait, we fit a model including an effect of syn-
onymous SNPs and an effect of SNPs within 5kb of a TSS. Shown are the estimated enrichments
parameters and 95% confidence intervals for the synonymous SNPs. B. Estimated proportion
of GWAS hits driven by synonymous SNPs. For each trait, using the model fit in A., we
estimated the proportion of GWAS signals driven by synonymous SNPs. Shown is this estimate
and its standard error.
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Figure 4. Annotation effects in the bone mineral density data. We estimated an enrichment
parameter for each annotation individually in the GWAS for A. bone density in the femoral neck
and B. bone density in the lumbar spine. Shown are the maximum likelihood estimates and 95%
confidence intervals. Annotations are ranked according to how much each improves the fit of the
model; shown are the 50 annotations that most improve the model (or if there were less than 50
significant annotations, all of the significant annotations). In red are the annotations included in
the combined model, and in pink are annotations that are statistically equivalent to those in the
combined model.
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Figure 5. Annotation effects in the GIANT data. We estimated an enrichment parameter for
each annotation individually in the GWAS for A. BMI and B. height. Shown are the maximum
likelihood estimates and 95% confidence intervals. Annotations are ranked according to how much
each improves the fit of the model; shown are the 50 annotations that most improve the model
(or if there were less than 50 significant annotations, all of the significant annotations). In red are
the annotations included in the combined model, and in pink are annotations that are statistically
equivalent to those in the combined model.
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Figure 6. Annotation effects in the Crohn’s disease and fasting glucose data. We es-
timated an enrichment parameter for each annotation individually in the GWAS for A. Crohn’s
disease and B. fasting glucose. Shown are the maximum likelihood estimates and 95% confidence
intervals. Annotations are ranked according to how much each improves the fit of the model; shown
are the 50 annotations that most improve the model (or if there were less than 50 significant an-
notations, all of the significant annotations). In red are the annotations included in the combined
model, and in pink are annotations that are statistically equivalent to those in the combined model.
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Figure 7. Annotation effects in the red blood cell data. We estimated an enrichment
parameter for each annotation individually in the GWAS for A. hemoglobin levels and B. mean
cellular hemoglobin. Shown are the maximum likelihood estimates and 95% confidence intervals.
Annotations are ranked according to how much each improves the fit of the model; shown are the
50 annotations that most improve the model (or if there were less than 50 significant annotations,
all of the significant annotations). In red are the annotations included in the combined model, and
in pink are annotations that are statistically equivalent to those in the combined model.
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Figure 8. Annotation effects in the red blood cell data. We estimated an enrichment
parameter for each annotation individually in the GWAS for A. mean corpuscular hemoglobin
concentration and B. mean red cell volume. Shown are the maximum likelihood estimates and
95% confidence intervals. Annotations are ranked according to how much each improves the fit of
the model; shown are the 50 annotations that most improve the model (or if there were less than
50 significant annotations, all of the significant annotations). In red are the annotations included
in the combined model, and in pink are annotations that are statistically equivalent to those in the
combined model.
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Figure 9. Annotation effects in the red blood cell data. We estimated an enrichment
parameter for each annotation individually in the GWAS for A. packed cell volume and B. mean red
cell count. Shown are the maximum likelihood estimates and 95% confidence intervals. Annotations
are ranked according to how much each improves the fit of the model; shown are the 50 annotations
that most improve the model (or if there were less than 50 significant annotations, all of the
significant annotations). In red are the annotations included in the combined model, and in pink
are annotations that are statistically equivalent to those in the combined model.
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Figure 10. Annotation effects in the lipids data. We estimated an enrichment parameter
for each annotation individually in the GWAS for A. triglyceride levels and B. total cholesterol.
Shown are the maximum likelihood estimates and 95% confidence intervals. Annotations are ranked
according to how much each improves the fit of the model; shown are the 50 annotations that most
improve the model (or if there were less than 50 significant annotations, all of the significant anno-
tations). In red are the annotations included in the combined model, and in pink are annotations
that are statistically equivalent to those in the combined model.
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Figure 11. Annotation effects in the lipids data. We estimated an enrichment parameter for
each annotation individually in the GWAS for A. HDL levels and B. LDL levels. Shown are the
maximum likelihood estimates and 95% confidence intervals. Annotations are ranked according to
how much each improves the fit of the model; shown are the 50 annotations that most improve
the model (or if there were less than 50 significant annotations, all of the significant annotations).
In red are the annotations included in the combined model, and in pink are annotations that are
statistically equivalent to those in the combined model.
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Figure 12. Annotation effects in the platelet data. We estimated an enrichment parameter
for each annotation individually in the GWAS for A. mean platelet volume and B. platelet count.
Shown are the maximum likelihood estimates and 95% confidence intervals. Annotations are ranked
according to how much each improves the fit of the model; shown are the 50 annotations that most
improve the model (or if there were less than 50 significant annotations, all of the significant anno-
tations). In red are the annotations included in the combined model, and in pink are annotations
that are statistically equivalent to those in the combined model.
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Figure 13. Correlated patterns of enrichment across traits. We estimated an enrichment
parameter for each of 450 annotations for each of the 18 traits. For each pair of traits, we then
estimated the Spearman correlation coefficient between the enrichment parameters. Plotted are
these correlation coefficients. Orders of rows and columns were chosen by hierarchical clustering in
R [R Core Team, 2013].
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Figure 14. Combined models for nine traits. For each trait, we built a combined model of
annotations using the algorithm presented in the Methods from the main text. Shown are the
maximum likelihood estimates and 95% confidence intervals for all annotations included in each
model. Note that though these are the maximum likelihood estimates, model choice was done
using a penalized likelihood. In parentheses next to each annotation (expect for those relating to
distance to transcription start sites), we show the total number of annotations that are statistically
equivalent to the included annotation in a conditional analysis. For the other nine traits, see Figure
4 in the main text. *This annotation of DNase-I hypersensitive sites in fetal kidney (renal pelvis)
has a positive effect when treated alone; see Supplementary Text for discussion.
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Figure 15. Calibrating a PPA threshold similar to a P-value threshold. For each of the
four phenotypes in the lipids data, we plot the number of “true positives” and “false positives”
obtained by different statistical thresholds; see Supplementary Text for details. Points show the
positions of the thresholds used in the paper.
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Figure 16. Robustness of parameter estimates to preset parameters. A. Prior variance
on effect size. We estimated an enrichment parameter for each annotation in Crohn’s disease
using prior variances of 0.1 or 0.5. Shown are the estimates for all annotations with 95% confidence
intervals that did not overlap 0 in at least one of the two runs. In red is the y = x line. B. Window
size. We estimated an enrichment parameter for each annotation in Crohn’s disease using window
sizes of 5,000 and 10,000 SNPs. Shown are the estimates for all annotations with 95% confidence
intervals that did not overlap 0 in at least one of the two runs. In red is the y = x line.
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Phenotype λGC (before imputation) λGC (after imputation)
Height 1.04 0.99
BMI 1.04 0.97
BMD (femoral neck) 1.0 0.92
BMD (lumbar spine) 1.0 0.93
Crohn’s 1.27 0.71
FG 1.08 0.97
HB 1.07 0.99
MCH 1.13 1.0
MCHC 1.07 0.85
MCV 1.13 1.0
PCV 1.09 0.97
RBC 1.14 1.01
TC 1.0 0.93
TG 1.0 0.92
HDL 1.0 0.94
LDL 1.0 0.93
PLT 1.08 1.01
MPV 1.04 0.96
Table 1: Genomic control inflation factors before and after imputation. We show λGC
[Bacanu et al., 2002] before and after imputation for all 18 GWAS included in this study.
Phenotype Proportion [95% CI]
BMI 0.022 [0.013, 0.032]
FNBMD 0.028 [0.019, 0.040]
LSBMD 0.028 [0.019, 0.041]
Crohn’s 0.078 [0.059, 0.10]
FG 0.020 [0.012, 0.03]
HB 0.010 [0.006, 0.015]
HDL 0.034 [0.026, 0.044]
Height 0.131 [0.111, 0.153]
LDL 0.034 [0.026, 0.045]
MCH 0.035 [0.025, 0.047]
MCHC 0.018 [0.011, 0.027]
MCV 0.046 [0.034, 0.059]
MPV 0.025 [0.017, 0.035]
PCV 0.003 [0.002, 0.005]
PLT 0.036 [0.028, 0.047]
RBC 0.023 [0.016, 0.033]
TC 0.052 [0.040, 0.067]
TG 0.023 [0.015, 0.032]
Table 2: Estimates of the fraction of regions containing an associated SNP for each
phenotype. We show the estimates of 1
1+e−κ , the proportion of regions from the middle third of
the distribution of gene density that contain associated SNPs (see Equation 7 in the main text),
along with the 95% confidence interval of this parameter.
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Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
BE2 C-DS14625
DNAse-I in BE(2)-C
neuroblastoma cell line
5.25 [3.09, 7.10] 5.15 5.60 [3.51, 7.47]
HUVEC PF
Genome segmentation in
HUVEC cells:
promoter-flanking
7.47 [3.90,9.91] 7.18 8.51 [5.41, 10.62]
Table 3: Combined model learned for BMI. Shown are the exact annotation names and
parameters learned for BMI, along with the penalized effect sizes and the effect of each annotation
in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation: top
1/3 of gene density
0.89 [0.01, 1.62] 0.88 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.05 [-2.68, 0.12] -0.95 NA
fHeart-DS12810 DNase-I in fetal heart 2.83 [1.11, 4.40] 2.45 4.83 [3.08, 6.43]
fHeart-DS16621 DNase-I in fetal heart 2.12 [0.50, 3.64] 2.21 4.47 [2.76, 6.03]
Table 4: Combined model learned for bone mineral density (femur). Shown are the exact
annotation names and parameters learned for FNBMD, along with the penalized effect sizes and
the effect of each annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation: top
1/3 of gene density
0.52 [-0.40, 1.27] 0.53 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.49 [-3.65, -0.13] -1.33 NA
HSMM D-DS15542
DNase-I in skeletal
muscle myoblasts
4.23 [2.24, 5.97] 3.75 3.90 [1.98, 5.58]
Table 5: Combined model learned for bone mineral density (spine). Shown are the exact
annotation names and parameters learned for LSBMD, along with the penalized effect sizes and
the effect of each annotation in a single-annotation model.
26
Annotation Description log2(Effect) Effect [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.18 [0.61, 1.72] 1.18 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-2.18 [-4.10, -0.92] -2.03 NA
fSkin fibro upper back-DS19696
DNase-I in fetal skin
fibroblasts from the
upper back
5.21 [4.08, 6.20] 4.78 3.84 [2.63, 4.89]
gm12878.combined.R
Genome segmentation of
GM12878: repressed
-1.83 [-3.06, -0.78] -1.79 -2.35 [-4.50, -1.05]
fSkin fibro abdomen-DS19561
DNase-I in fetal skin
fibroblasts from
abdomen
-2.34 [-3.85, -1.18] -1.86 2.77 [1.27, 3.94]
huvec.combined.T
Genome segmentation of
HUVEC: transcribed
1.20 [0.25, 2.15] 1.17 1.63 [0.61, 2.65]
Distance to TSS [0-5 kb] From 0-5 kb from a TSS 1.18 [0.17, 2.15] 1.17 NA
Distance to TSS [5-10 kb]
From 5-10 kb from a
TSS
0.45 [-1.38, 1.75] 0.40 NA
Table 6: Combined model learned for Crohn’s disease. Shown are the exact annotation
names and parameters learned for Crohn’s disease, along with the penalized effect sizes and the
effect of each annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
fStomach-DS17878
DNase-I in fetal
stomach
3.66 [1.66, 5.31] 3.62 3.82 [1.66, 5.50]
Nonsynonymous nonsynonymous SNPs 4.28 [1.53, 6.10] 4.13 4.95 [1.40, 6.95]
Distance to TSS [0-5 kb] From 0-5 kb from a TSS 1.83 [0.22, 3.40] 1.75 NA
Distance to TSS [5-10 kb]
From 5-10 kb from a
TSS
2.68 [0.76, 4.28] 2.54 NA
Table 7: Combined model learned for fasting glucose. Shown are the exact annotation
names and parameters learned for FG, along with the penalized effect sizes and the effect of each
annotation in a single-annotation model.
Annotation Description log2(Effect) 95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
2.78 [1.98, 3.46] 2.80 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-40.6 [− inf, -0.72] -5.44 NA
HMVEC dAd-DS12957
DNase-I in
microvascular
endothelium
4.91 [3.09, 6.52] 4.86 4.43 [2.60, 6.02]
k562.combined.T
Genome segmentation of
K562: transcribed
2.15 [0.49, 3.77] 2.12 1.82 [0.01, 3.55]
Table 8: Combined model learned for hemoglobin levels. Shown are the exact annotation
names and parameters learned for hemoglobin levels, along with the penalized effect sizes and the
effect of each annotation in a single-annotation model.
27
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.69 [1.13, 2.19] 1.56 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.17 [-0.13, 0.69] -0.20 NA
hepg2.combined.R
Genome segmentation of
HepG2: repressed
-1.83 [-3.12, -0.68] -1.79 -3.35 [-4.63, -2.19]
hepg2.combined.TSS
Genome segmentation of
HepG2: TSS
3.10 [1.79, 4.20] 2.84 5.09 [3.91, 6.16]
ens coding exons Ensembl: coding exons 3.16 [1.51, 4.40] 2.73 4.31 [2.73, 5.55]
k562.combined.R
Genome segmentation of
K562: repressed
-1.43 [-2.65, -0.30] -1.43 -2.90 [-4.08, -1.79]
Table 9: Combined model learned for HDL levels. Shown are the exact annotation names and
parameters learned for HDL, along with the penalized effect sizes and the effect of each annotation
in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.50 [1.13, 1.86] 1.49 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-0.95 [-1.62, -0.36] -0.94 NA
helas3.combined.R
Genome segmentation of
HeLa: repressed
-1.50 [-2.39, -0.71] -1.50 -2.74 [-3.78, -1.85]
fMuscle lower limb-DS18174
DNase-I in fetal muscle
from lower limb
2.27 [1.50, 3.02] 2.24 3.61 [2.81, 4.40]
Nonsynonymous Nonsynonymous SNPs 3.74 [2.55, 4.65] 3.58 4.27 [2.77, 5.32]
fLung-DS15573 DNase-I in fetal lung 2.09 [1.30, 2.80] 2.05 3.77 [2.97, 4.50]
huvec.combined.T
Genome segmentation of
HUVEC: transcribed
1.27 [0.52, 1.96] 1.24 1.63 [0.89, 2.34]
ens utr3 exons Ensembl: 3’ UTRs 1.57 [0.00, 2.64] 1.54 2.93 [1.34, 3.98]
Table 10: Combined model learned for height. Shown are the exact annotation names and
parameters learned for height, along with the penalized effect sizes and the effect of each annotation
in a single-annotation model.
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Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.77 [1.21, 2.27] 1.72 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-0.72 [-1.98, 0.25] -0.71 NA
hepg2.combined.R
Genome segmentation of
HepG2: repressed
-2.78 [-4.36, -1.51] -2.70 -3.04 [-4.70, -1.76]
Nonsynonymous Nonsynonymous SNPs 4.24 [2.74, 5.40] 3.97 4.89 [3.48, 6.02]
Distance to TSS [0-5 kb] From 0-5 kb from a TSS 3.13 [1.96, 4.56] 2.84 NA
Distance to TSS [5-10 kb]
From 5-10 kb from a
TSS
1.63 [-0.65, 3.12] 1.17 NA
Table 11: Combined model learned for LDL levels. Shown are the exact annotation names and
parameters learned for LDL, along with the penalized effect sizes and the effect of each annotation
in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.56 [0.94, 2.11] 1.51 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.17 [-2.80, -0.01] -1.10 NA
k562.combined.E
Genome segmentation of
K562: enhancers
3.68 [2.47, 4.75] 3.53 5.67 [4.49, 6.74]
k562.combined.R
Genome segmentation of
K562: repressed
-3.17 [-4.80, -1.86] -2.97 -3.94 [-5.57, -2.61]
hTH17-DS11039 DNase-I in Th17 T cells 2.21 [0.35, 3.51] 2.06 4.53 [2.93, 5.74]
Table 12: Combined model learned for mean cell hemoglobin. Shown are the exact anno-
tation names and parameters learned for MCH, along with the penalized effect sizes and the effect
of each annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.11 [0.09, 1.93] 1.17 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.57 [-4.41, 0.10] -1.36 NA
k562.combined.R
Genome segmentation of
K562: repressed
-3.81 [-7.43, -1.79] -3.42 -4.34 [-8.94, -2.27]
K562-DS9767 DNase-I in K562 cells 2.67 [0.61, 4.44] 2.47 4.46 [2.60, 6.22]
Nonsynonymous Nonsynonymous SNPs 4.66 [1.90, 6.52] 4.03 4.27 [0.97, 6.25]
Table 13: Combined model learned for mean corpuscular hemoglobin concentration.
Shown are the exact annotation names and parameters learned for MCHC, along with the penalized
effect sizes and the effect of each annotation in a single-annotation model.
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Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.36 [0.76, 1.86] 1.31 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.51 [-3.06, -0.39] -1.46 NA
k562.combined.R
Genome segmentation of
K562: repressed
-3.91 [-6.25, -2.38] -3.69 -5.24 [-7.76, -3.59]
k562.combined.E
Genome segmentation of
K562: enhancer
3.10 [1.86, 4.15] 2.96 5.67 [4.47, 6.77]
hTH17-DS11039 DNase-I in Th17 T cells 2.31 [0.81, 3.48] 2.25 5.40 [4.21, 6.46]
Nonsynonymous Nonsynonymous SNPs 4.54 [2.34, 5.92] 4.13 5.11 [3.26, 6.39]
CMK-DS12393
DNase-I in CMK
leukemia line
1.28 [0.04, 2.35] 1.34 4.52 [3.30, 5.64]
Distance to TSS [0-5 kb] From 0-5 kb from a TSS 0.38 [-1.59, 0.65] -0.33 NA
Distance to TSS [5-10 kb]
From 5-10 kb from a
TSS
0.89 [-0.40, 1.83] 0.84 NA
Table 14: Combined model learned for mean red cell volume. Shown are the exact anno-
tation names and parameters learned for MCV, along with the penalized effect sizes and the effect
of each annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.95 [1.30, 2.52] 1.88 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-2.06 [-4.73, -0.40] -1.63 NA
CD34-DS12274 DNase-I in CD34+ cells 3.02 [1.69, 4.26] 2.76 4.37 [2.99, 5.64]
gm12878.combined.T
Genome segmentation of
GM12878: transcribed
2.35 [1.07, 3.53] 1.83 1.86 [0.59, 3.04]
helas3.combined.E
Genome segmentation of
HeLa: enhancer
2.80 [0.75, 4.23] 2.27 3.35 [0.16, 5.09]
fSpleen-DS17448 DNase-I in fetal spleen 1.93 [0.59, 3.15] 1.88 3.65 [2.22, 4.92]
Table 15: Combined model learned for mean platelet volume. Shown are the exact anno-
tation names and parameters learned for MPV, along with the penalized effect sizes and the effect
of each annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
4.24 [3.36, 4.95] 3.72 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-40.60 [-inf, 0.94] -1.92 NA
Nonsynonymous Nonsynonymous SNPs 4.11 [1.34, 6.07] 3.61 5.34 [2.83, 7.23]
fStomach-DS17172
DNase-I in fetal
stomach
3.90 [1.40, 6.17] 3.48 4.78 [2.54, 7.03]
Table 16: Combined model learned for packed red cell volume. Shown are the exact
annotation names and parameters learned for PCV, along with the penalized effect sizes and the
effect of each annotation in a single-annotation model.
30
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.67 [2.81, 2.64] 2.14 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.63 [-3.40, -0.38] -1.51 NA
k562.combined.R
Genome segmentation
in K562: repressed
-1.60 [-2.63, -0.66] -1.60 -2.60 [-3.65, -1.64]
CD34-DS12274 DNase-I in CD34+ cells 1.82 [0.59, 2.86] 1.80 3.39 [2.24, 4.43]
Nonsynonymous Nonsynonymous SNPs 3.38 [1.31, 4.79] 3.00 3.98 [2.02, 5.38]
huvec.combined.E
Genome segmentation
in HUVEC: enhancers
1.67 [0.16, 2.84] 1.59 3.27 [1.82, 4.41]
helas3.combined.R
Genome segmentation
in HeLa: repressed
-1.17 [-2.37, -0.13] -1.14 -2.18 [-3.40, -1.11]
Table 17: Combined model learned for platelet count. Shown are the exact annotation
names and parameters learned for PLT, along with the penalized effect sizes and the effect of each
annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.99 [1.33, 2.58] 1.96 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-2.74 [-6.97, -0.59] -2.18 NA
fStomach-DS17878
DNAse-I in fetal
stomach
5.31 [3.87, 6.91] 4.83 4.83 [3.30, 6.45]
k562.combined.E
Genome segmentation of
K562: enhancer
1.53 [-0.04, 2.83] 1.56 4.28 [1.41, 5.90]
fKidney renal pelvis R-DS18663
DNase-I in fetal renal
pelvis
-3.49 [-7.68, -1.56] -2.80 2.48 [0.04, 4.17]
K562-DS9767
DNase-I in K562
leukemia line
2.28 [0.97, 3.58] 2.25 4.50 [2.97, 5.97]
Table 18: Combined model learned for red blood cell count. Shown are the exact annotation
names and parameters learned for RBC, along with the penalized effect sizes and the effect of each
annotation in a single-annotation model.
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Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.05 [0.48, 1.56] 1.04 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-1.40 [-2.74, -0.39] -1.34 NA
hepg2.combined.R
Genome segmentation of
HepG2: repressed
-2.90 [-4.36, -1.72] -2.84 -3.19 [-4.76, -1.95]
Nonsynonymous Nonsynonymous SNPs 4.36 [2.90, 5.48] 4.18 4.89 [3.51, 5.99]
Distance to TSS [0-5 kb] From 0-5 kb from a TSS 2.76 [1.62, 4.15] 2.58 NA
Distance to TSS [5-10 kb]
From 5-10 kb from a
TSS
1.88 [-0.27, 3.29] 1.56 NA
Table 19: Combined model learned for total cholesterol. Shown are the exact annotation
names and parameters learned for total cholesterol, along with the penalized effect sizes and the
effect of each annotation in a single-annotation model.
Annotation Description log2(Effect) [95% CI] Penalized effect Marginal effect [95% CI]
High gene density
Regional annotation:
top 1/3 of gene density
1.56 [0.85, 2.18] 1.49 NA
Low gene density
Regional annotation:
bottom 1/3 of gene
density
-0.82 [-2.65, 0.40] -0.78 NA
hepg2.combined.R
Genome segementation
of HepG2: repressed
-4.24 [-6.68, -2.47] -3.75 -4.56 [-7.11, -2.76]
ens utr3 exons Ensembl: 3’ UTRs 3.87 [2.11, 5.28] 3.46 4.60 [2.86, 6.03]
Table 20: Combined model learned for triglyceride levels. Shown are the exact annotation
names and parameters learned for triglycerides, along with the penalized effect sizes and the effect
of each annotation in a single-annotation model.
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PPA P-value combined
Phenotype True positives False positives True positives False positives True positives False positives
HDL 45 0 43 1 48 1
LDL 43 1 40 0 44 1
TC 47 0 51 0 51 0
TG 27 0 29 0 30 0
Table 21: Comparison of loci identified in the lipids data with different methods. We
ranked genomic regions in GWAS of four lipid traits according to their minimum P-value or posterior
probability of association from Teslovich et al. [2010]. We then evaluated false positives and false
negatives by comparison to a larger GWAS [Global Lipids Genetics Consortium et al., 2013]. See
Supplementary Text for details.
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